A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis. Sasaki, K., Gotlib, J. R., Mesa, R. A., Ravandi, F., Cortes, J. E., Kelly, P., Kutok, J., Kantarjian, H. M., Verstovsek, S. AMER SOC CLINICAL ONCOLOGY. 2014

View details for Web of Science ID 000358613203928